Passage BIO (PASG) Accounts Payables (2019 - 2026)
Passage BIO (PASG) posted quarterly Accounts Payables of $1.3 million for Q1 2026, down 10.15% year-over-year from $1.5 million in Q1 2025, and up 17.7% quarter-over-quarter from $1.1 million in Q4 2025.
Passage BIO (PASG) Accounts Payables (2019 - 2026) Analysis & Trends
Passage BIO's Accounts Payables history runs 8 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 10.15% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 10.15% YoY), while the FY2025 annual figure was $1.1 million, up 50.0% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.3 million, up from $1.1 million in the prior quarter.
- The five-year high for Accounts Payables was $9.1 million in Q1 2022, with the low at $621000.0 in Q2 2024.
- The 5-year median for Accounts Payables is $1.7 million (2024), against an average of $2.8 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables plunged 81.64% in 2024, then soared 285.67% in 2025.
- Passage BIO's Accounts Payables stood at $4.1 million in 2022, then sank by 68.07% to $1.3 million in 2023, then slumped by 42.84% to $742000.0 in 2024, then jumped by 50.0% to $1.1 million in 2025, then rose by 17.7% to $1.3 million in 2026.
- Business Quant data shows PASG's Accounts Payables at $1.3 million in Q1 2026, $1.1 million in Q4 2025, and $952000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | 902,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 902,000.00 |
| Mar 31, 2026 | 1.31 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 952,000.00 |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 742,000.00 |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 621,000.00 |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | 1.30 Mn |
| Sep 30, 2023 | 2.75 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 4.07 Mn |
| Sep 30, 2022 | 4.51 Mn |
| Jun 30, 2022 | 8.21 Mn |
| Mar 31, 2022 | 9.14 Mn |
| Dec 31, 2021 | 9.45 Mn |
| Sep 30, 2021 | 8.98 Mn |